

Cover Story
ClinicalRegulatory NewsTrials & Tribulations
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research